1. Home
  2. BESS vs COCP Comparison

BESS vs COCP Comparison

Compare BESS & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BESS

Bimergen Energy Corporation Common Stock

N/A

Current Price

$4.99

Market Cap

16.6M

Sector

N/A

ML Signal

N/A

Logo Cocrystal Pharma Inc.

COCP

Cocrystal Pharma Inc.

HOLD

Current Price

$0.97

Market Cap

13.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BESS
COCP
Founded
1998
2006
Country
United States
United States
Employees
3
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.6M
13.7M
IPO Year
N/A
2011

Fundamental Metrics

Financial Performance
Metric
BESS
COCP
Price
$4.99
$0.97
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
837.4K
98.1K
Earning Date
03-31-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
54.65
EPS
N/A
N/A
Revenue
N/A
$12,712,091.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.00
$0.86
52 Week High
$5.08
$2.19

Technical Indicators

Market Signals
Indicator
BESS
COCP
Relative Strength Index (RSI) 61.67 34.64
Support Level $2.03 $0.90
Resistance Level $5.04 $1.11
Average True Range (ATR) 0.75 0.06
MACD 0.05 0.00
Stochastic Oscillator 85.16 15.78

Price Performance

Historical Comparison
BESS
COCP

About BESS Bimergen Energy Corporation Common Stock

Bimergen Energy Corp is a renewable energy project developer that enables the clean energy transition and provides critical grid stability via solutions across a range of applications through portfolio of utility-scale Battery Energy Storage System (BESS) and solar development projects. Its portfolio includes approximately 23 development-stage utility-scale BESS projects with a projected total storage capacity of around 1.965 gigawatts (GW) and approximately 13 development-stage solar energy projects expected to generate around 1.640 GW upon completion and operation.

About COCP Cocrystal Pharma Inc.

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.

Share on Social Networks: